BSE Live
Jan 23, 16:01Prev. Close
1217.15
Open Price
1218.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 23, 15:57Prev. Close
1217.50
Open Price
1230.00
Bid Price (Qty.)
1235.60 (90)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 7,679.50 | 7,201.00 | 6,048.50 | 3,061.40 | 2,883.50 | |
| Net CashFlow From Operating Activities | 4,642.80 | 4,543.30 | 5,887.50 | 2,810.80 | 3,570.30 | |
| Net Cash Used In Investing Activities | -5,807.70 | -4,028.30 | -4,137.30 | -2,638.70 | -2,266.00 | |
| Net Cash Used From Financing Activities | 1,891.10 | -376.30 | -2,686.10 | -242.20 | -29.80 | |
| Foreign Exchange Gains / Losses | 22.40 | -5.90 | 28.60 | 73.30 | 11.30 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 748.60 | 132.80 | -907.30 | 3.20 | 1,285.80 | |
| Cash And Cash Equivalents Begin of Year | 710.70 | 577.90 | 1,485.20 | 1,482.00 | 196.20 | |
| Cash And Cash Equivalents End Of Year | 1,459.30 | 710.70 | 577.90 | 1,485.20 | 1,482.00 |
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
22.01.2026
16.01.2026
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz